This BCC market research report provides a detailed overview and thorough analysis of the present and future global market for breast cancer diagnostics and drug technologies. It provides detailed analysis of the breast cancer drug and diagnostics markets, as well as the currently used personalized, predictive and companion tests and their markets. The research also includes market characterization, opportunities, the unmet needs associated with breast cancer, competitive assessment, product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition and the key players of the breast cancer market.
This report includes products in this market and detailed analyses of markets and competitive environments. It also analyzes current and future market prospects. It provides a comprehensive review of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to companion tests, tumor markers and gene profiling assays relevant for breast cancer prognosis and diagnosis. The analysis reviews technological developments, product innovations and recent strategic industry activity of major players across different product categories. It analyzes their strengths and weaknesses, opportunities and threats facing various devices and drugs in this market space and developments already on the market. It discusses the major issues involved in the research and development (R&D) of more effective devices for drug delivery to the lungs, along with new products in development.
REASONS FOR DOING THE STUDY
According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with breast cancer annually. It is no longer necessary for one breast cancer treatment to fit all cases, a concept that should be welcome news for physicians and their patients alike. Personalized medicine is relatively new to the market research report format, and it provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The scope of this report covers global companies developing tests relevant for breast cancer prognosis and diagnosis. This study describes current products in each area, identifies current market participants, and most importantly, notes the trends that will affect further product development in this area.
Companion diagnostics is also a part of the personalized medicine revolution. The field evolved as a continuation of biomarker studies and diagnostics testing. The breast cancer predictive testing segment of the industry is still growing; it has a number of successful FDA–approved products. This study will provide knowledge of the current state of the companion diagnostics industry and the new technologies in assay development. More importantly, it will describe potential and novel commercial developments in this area. The report will also provide an overview covering major biotechnology and pharma companies involved in developing innovative, targeted breast cancer treatments that address major unmet medical needs to advance cancer care. In addition, the report also provides information regarding the less-developed sectors of this market and presents a list of current companies that have new predictive testing products and drugs in development for breast cancer.
Buy your copy of this report @ http://www.reportsnreports.com/reports/168368-breast-cancer-diagnostic-and-drug-technologies-global-markets.html
Report Details:
Published: June 2012
No. of Pages: 166
Price: Single User License:US$ 4850 Corporate User License: US$ 8500
REASONS FOR DOING THE STUDY
According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with breast cancer annually. It is no longer necessary for one breast cancer treatment to fit all cases, a concept that should be welcome news for physicians and their patients alike. Personalized medicine is relatively new to the market research report format, and it provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The scope of this report covers global companies developing tests relevant for breast cancer prognosis and diagnosis. This study describes current products in each area, identifies current market participants, and most importantly, notes the trends that will affect further product development in this area.
Companion diagnostics is also a part of the personalized medicine revolution. The field evolved as a continuation of biomarker studies and diagnostics testing. The breast cancer predictive testing segment of the industry is still growing; it has a number of successful FDA–approved products. This study will provide knowledge of the current state of the companion diagnostics industry and the new technologies in assay development. More importantly, it will describe potential and novel commercial developments in this area. The report will also provide an overview covering major biotechnology and pharma companies involved in developing innovative, targeted breast cancer treatments that address major unmet medical needs to advance cancer care. In addition, the report also provides information regarding the less-developed sectors of this market and presents a list of current companies that have new predictive testing products and drugs in development for breast cancer.
SCOPE AND FORMAT
This report will provide an update and on overview on predictive testing in breast cancer diagnostics and drug technologies and global markets. The study’s objective is to review the tumor marker-based predictive companion tests and drugs for breast cancer, and then assess their global growth potential over a five-year period from 2011 to 2016. Review includes global markets for breast cancer incidence, current drugs, new developments, predictive diagnostic tests, market trends and new technologies, and developments and forecast trends for the use of current tests for better diagnosis and prognosis for breast cancer through 2016. Important tests, technologies and developments; market share by drug, test, current products on the market and market share by company or product; and statistical information for types of breast cancer prevalence globally, with special emphasis on the U.S. market, are discussed. The report focuses on tumor marker-based testing that provides vital information about the cancer. These tests can help determine the appropriate medicine and timing of treatment to address the disease most effectively. The report also includes current issues and trends affecting the industry. The report covers products in development, new technologies, trends, alliances, patents and mergers. It offers market data with respect to segments and geography. Other breast cancer detection and screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this report.
INTENDED AUDIENCE
This report is an exhaustive study on the global breast cancer market, giving crucial statistics and analysis on existing drugs, diagnostic technologies, latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities and market shares of key players and drugs. This information may prove crucial for the firms or investors seeking opportunities in the concerned sector. This report shows tests currently being used for breast cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. It provides market data for 2010 to 2016, and also covers commercial prospects for breast cancer diagnostic and prognostic assays.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news, and paid and free databases. The base year of the report is 2010, with forecast data provided through 2016. Historical, base year and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of breast cancer incidence, development of the disease, drugs currently used and diagnostic technologies based on tumor markers for accurate diagnosis and aid in deciding treatment plans for patients. The new analysis reviews technological developments, product innovations and introductions, and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. A comprehensive and exhaustive search of the literature on breast cancer assay development and already–marketed products, breast cancer global incidence and latest drug developments was conducted. These secondary sources included scientific-related journals and articles, textbooks, press releases, marketing literature, other product or promotional literature, annual reports and security analyst reports. Patent searches and analyses were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academic, technology transfer offices and consulting companies.
ANALYST CREDENTIALS
Usha Nagavarapu is a pharmaceutical professional with experience in scientific and alliance development. This includes more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including IND enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early-start-ups to fulfill operational obligations while minimizing overall operational cost and burden.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
Examine the complete BCC Research catalog of market research reports and place direct orders.
Subscribe to any of BCC Research’s many industry newsletters.
Read announcements of recently published reports and newly launched newsletters.
Register for its well-known conferences.
Request additional information on any BCC research product.
Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
This report includes products in this market and detailed analyses of markets and competitive environments. It also analyzes current and future market prospects. It provides a comprehensive review of emerging breast cancer personalized and predictive diagnostic tests, particularly with regard to companion tests, tumor markers and gene profiling assays relevant for breast cancer prognosis and diagnosis. The analysis reviews technological developments, product innovations and recent strategic industry activity of major players across different product categories. It analyzes their strengths and weaknesses, opportunities and threats facing various devices and drugs in this market space and developments already on the market. It discusses the major issues involved in the research and development (R&D) of more effective devices for drug delivery to the lungs, along with new products in development.
REASONS FOR DOING THE STUDY
According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with breast cancer annually. It is no longer necessary for one breast cancer treatment to fit all cases, a concept that should be welcome news for physicians and their patients alike. Personalized medicine is relatively new to the market research report format, and it provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The scope of this report covers global companies developing tests relevant for breast cancer prognosis and diagnosis. This study describes current products in each area, identifies current market participants, and most importantly, notes the trends that will affect further product development in this area.
Companion diagnostics is also a part of the personalized medicine revolution. The field evolved as a continuation of biomarker studies and diagnostics testing. The breast cancer predictive testing segment of the industry is still growing; it has a number of successful FDA–approved products. This study will provide knowledge of the current state of the companion diagnostics industry and the new technologies in assay development. More importantly, it will describe potential and novel commercial developments in this area. The report will also provide an overview covering major biotechnology and pharma companies involved in developing innovative, targeted breast cancer treatments that address major unmet medical needs to advance cancer care. In addition, the report also provides information regarding the less-developed sectors of this market and presents a list of current companies that have new predictive testing products and drugs in development for breast cancer.
Buy your copy of this report @ http://www.reportsnreports.com/reports/168368-breast-cancer-diagnostic-and-drug-technologies-global-markets.html
Report Details:
Published: June 2012
No. of Pages: 166
Price: Single User License:US$ 4850 Corporate User License: US$ 8500
REASONS FOR DOING THE STUDY
According to the National Cancer Institute, more than 200,000 women in the U.S. are diagnosed with breast cancer annually. It is no longer necessary for one breast cancer treatment to fit all cases, a concept that should be welcome news for physicians and their patients alike. Personalized medicine is relatively new to the market research report format, and it provides business tools to evaluate new commercial opportunities in diagnostics and biomarker fields. The scope of this report covers global companies developing tests relevant for breast cancer prognosis and diagnosis. This study describes current products in each area, identifies current market participants, and most importantly, notes the trends that will affect further product development in this area.
Companion diagnostics is also a part of the personalized medicine revolution. The field evolved as a continuation of biomarker studies and diagnostics testing. The breast cancer predictive testing segment of the industry is still growing; it has a number of successful FDA–approved products. This study will provide knowledge of the current state of the companion diagnostics industry and the new technologies in assay development. More importantly, it will describe potential and novel commercial developments in this area. The report will also provide an overview covering major biotechnology and pharma companies involved in developing innovative, targeted breast cancer treatments that address major unmet medical needs to advance cancer care. In addition, the report also provides information regarding the less-developed sectors of this market and presents a list of current companies that have new predictive testing products and drugs in development for breast cancer.
SCOPE AND FORMAT
This report will provide an update and on overview on predictive testing in breast cancer diagnostics and drug technologies and global markets. The study’s objective is to review the tumor marker-based predictive companion tests and drugs for breast cancer, and then assess their global growth potential over a five-year period from 2011 to 2016. Review includes global markets for breast cancer incidence, current drugs, new developments, predictive diagnostic tests, market trends and new technologies, and developments and forecast trends for the use of current tests for better diagnosis and prognosis for breast cancer through 2016. Important tests, technologies and developments; market share by drug, test, current products on the market and market share by company or product; and statistical information for types of breast cancer prevalence globally, with special emphasis on the U.S. market, are discussed. The report focuses on tumor marker-based testing that provides vital information about the cancer. These tests can help determine the appropriate medicine and timing of treatment to address the disease most effectively. The report also includes current issues and trends affecting the industry. The report covers products in development, new technologies, trends, alliances, patents and mergers. It offers market data with respect to segments and geography. Other breast cancer detection and screening technologies and markets (e.g., mammography, ultrasound, biopsy) are not included in this report.
INTENDED AUDIENCE
This report is an exhaustive study on the global breast cancer market, giving crucial statistics and analysis on existing drugs, diagnostic technologies, latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities and market shares of key players and drugs. This information may prove crucial for the firms or investors seeking opportunities in the concerned sector. This report shows tests currently being used for breast cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. It provides market data for 2010 to 2016, and also covers commercial prospects for breast cancer diagnostic and prognostic assays.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news, and paid and free databases. The base year of the report is 2010, with forecast data provided through 2016. Historical, base year and forecast data are provided for each market segment of this report.
The report provides a comprehensive review of breast cancer incidence, development of the disease, drugs currently used and diagnostic technologies based on tumor markers for accurate diagnosis and aid in deciding treatment plans for patients. The new analysis reviews technological developments, product innovations and introductions, and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. A comprehensive and exhaustive search of the literature on breast cancer assay development and already–marketed products, breast cancer global incidence and latest drug developments was conducted. These secondary sources included scientific-related journals and articles, textbooks, press releases, marketing literature, other product or promotional literature, annual reports and security analyst reports. Patent searches and analyses were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academic, technology transfer offices and consulting companies.
ANALYST CREDENTIALS
Usha Nagavarapu is a pharmaceutical professional with experience in scientific and alliance development. This includes more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including IND enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early-start-ups to fulfill operational obligations while minimizing overall operational cost and burden.
BCC ON-LINE SERVICES
BCC Research offers an online information retrieval service. Its home page, located at www.bccresearch.com, enables readers to:
Examine the complete BCC Research catalog of market research reports and place direct orders.
Subscribe to any of BCC Research’s many industry newsletters.
Read announcements of recently published reports and newly launched newsletters.
Register for its well-known conferences.
Request additional information on any BCC research product.
Take advantage of special offers.
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal or accounting advice, nor should it serve as a corporate policy guide, laboratory manual or an endorsement of any product, as much of the information is of a speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or from its use.
